[{"id":"36ca1f5c-c2f6-4841-9b20-252eb2f23150","acronym":"","url":"https://clinicaltrials.gov/study/NCT04987996","created_at":"2021-08-03T18:52:59.526Z","updated_at":"2024-07-02T16:35:46.330Z","phase":"Phase 2","brief_title":"GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients","source_id_and_acronym":"NCT04987996","lead_sponsor":"Providence Health \u0026 Services","biomarkers":" CD8 • IL2RA • CCR7 • CD27 • LGALS3 • FAS • FOXP3 • ISG20","pipe":"","alterations":" ","tags":["CD8 • IL2RA • CCR7 • CD27 • LGALS3 • FAS • FOXP3 • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • belapectin (GR-MD-02)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/01/2023","start_date":" 07/01/2023","primary_txt":" Primary completion: 07/01/2027","primary_completion_date":" 07/01/2027","study_txt":" Completion: 07/01/2031","study_completion_date":" 07/01/2031","last_update_posted":"2023-06-06"},{"id":"985dbe59-edc4-40c6-b4c4-daf7da0b5372","acronym":"TRASTS","url":"https://clinicaltrials.gov/study/NCT02275286","created_at":"2022-06-01T12:55:54.963Z","updated_at":"2024-07-02T16:35:46.759Z","phase":"Phase 1/2","brief_title":"Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients","source_id_and_acronym":"NCT02275286 - TRASTS","lead_sponsor":"Grupo Espanol de Investigacion en Sarcomas","biomarkers":" FAS","pipe":"","alterations":" ","tags":["FAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yondelis (trabectedin)"],"overall_status":"Recruiting","enrollment":" Enrollment 199","initiation":"Initiation: 11/01/2014","start_date":" 11/01/2014","primary_txt":" Primary completion: 06/01/2028","primary_completion_date":" 06/01/2028","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2023-05-31"},{"id":"c0fa7b11-1ff5-4745-b5b0-98d6ce2329bd","acronym":"","url":"https://clinicaltrials.gov/study/NCT00280202","created_at":"2021-01-18T00:57:15.755Z","updated_at":"2024-07-02T16:35:53.488Z","phase":"","brief_title":"Detection of Genetic Markers of Lung Cancer","source_id_and_acronym":"NCT00280202","lead_sponsor":"University of Pittsburgh","biomarkers":" FASLG • FADD • FAS • KRT19","pipe":" | ","alterations":" TILs","tags":["FASLG • FADD • FAS • KRT19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TILs"],"overall_status":"Recruiting","enrollment":" Enrollment 6000","initiation":"Initiation: 06/01/1996","start_date":" 06/01/1996","primary_txt":" Primary completion: 12/01/2050","primary_completion_date":" 12/01/2050","study_txt":" Completion: 12/01/2050","study_completion_date":" 12/01/2050","last_update_posted":"2023-03-13"},{"id":"d3399d53-3142-4fb8-8731-3da5f0cf0026","acronym":"TITAN-RCC","url":"https://clinicaltrials.gov/study/NCT02917772","created_at":"2021-08-04T19:53:08.805Z","updated_at":"2025-02-25T14:36:42.250Z","phase":"Phase 2","brief_title":"Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma","source_id_and_acronym":"NCT02917772 - TITAN-RCC","lead_sponsor":"AIO-Studien-gGmbH","biomarkers":" CD8 • PD-1 • PD-L2 • IL2RA • CD69 • ICOS • IL10 • CD14 • CD27 • LAMP1 • ITGAM • FAS • FOXP3 • IL17A • IL3RA • ITGAX • B3GAT1 • CD1C • CLEC4C","pipe":" | ","alterations":" PD-L1 expression","tags":["CD8 • PD-1 • PD-L2 • IL2RA • CD69 • ICOS • IL10 • CD14 • CD27 • LAMP1 • ITGAM • FAS • FOXP3 • IL17A • IL3RA • ITGAX • B3GAT1 • CD1C • CLEC4C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab)"],"overall_status":"Completed","enrollment":" Enrollment 200","initiation":"Initiation: 10/01/2016","start_date":" 10/01/2016","primary_txt":" Primary completion: 10/01/2021","primary_completion_date":" 10/01/2021","study_txt":" Completion: 10/01/2022","study_completion_date":" 10/01/2022","last_update_posted":"2022-10-06"},{"id":"a007902a-0a7f-41d6-85c9-d3d6c51f4f3e","acronym":"","url":"https://clinicaltrials.gov/study/NCT02689453","created_at":"2021-01-18T13:07:06.175Z","updated_at":"2024-07-02T16:36:11.245Z","phase":"Phase 1","brief_title":"Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)","source_id_and_acronym":"NCT02689453","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD8 • TNFRSF8 • CCR4 • IL2RA • CD4 • NCAM1 • CCR7 • CD52 • FAS • ISG20","pipe":" | ","alterations":" IL2RA expression","tags":["CD8 • TNFRSF8 • CCR4 • IL2RA • CD4 • NCAM1 • CCR7 • CD52 • FAS • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IL2RA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Campath (alemtuzumab) • rhIL-15"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 01/19/2017","start_date":" 01/19/2017","primary_txt":" Primary completion: 06/15/2021","primary_completion_date":" 06/15/2021","study_txt":" Completion: 06/15/2021","study_completion_date":" 06/15/2021","last_update_posted":"2022-04-29"},{"id":"c0bf121c-6f22-4255-bac5-d33472b5919a","acronym":"MITO CERV 3","url":"https://clinicaltrials.gov/study/NCT04238988","created_at":"2021-01-18T20:36:32.057Z","updated_at":"2025-02-25T16:09:53.518Z","phase":"Phase 2","brief_title":"Carboplatin-Paclitaxel-Pembrolizumab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer","source_id_and_acronym":"NCT04238988 - MITO CERV 3","lead_sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","biomarkers":" PD-L1 • PD-1 • IL6 • CTLA4 • PD-L2 • CD4 • ICOS • IL10 • FAS • FOXP3 • TNFSF4","pipe":"","alterations":" ","tags":["PD-L1 • PD-1 • IL6 • CTLA4 • PD-L2 • CD4 • ICOS • IL10 • FAS • FOXP3 • TNFSF4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • paclitaxel"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 02/18/2021","start_date":" 02/18/2021","primary_txt":" Primary completion: 09/01/2023","primary_completion_date":" 09/01/2023","study_txt":" Completion: 09/01/2023","study_completion_date":" 09/01/2023","last_update_posted":"2021-08-27"},{"id":"a4f66c58-b801-4e04-8f10-03d510d61f4a","acronym":"MK-4166-001","url":"https://clinicaltrials.gov/study/NCT02132754","created_at":"2021-01-18T09:53:38.686Z","updated_at":"2024-07-02T16:36:35.436Z","phase":"Phase 1","brief_title":"Study of MK-4166 and MK-4166 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4166-001)","source_id_and_acronym":"NCT02132754 - MK-4166-001","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" TNFA • IL2RA • CD4 • FAS","pipe":"","alterations":" ","tags":["TNFA • IL2RA • CD4 • FAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • MK-4166"],"overall_status":"Completed","enrollment":" Enrollment 116","initiation":"Initiation: 06/27/2014","start_date":" 06/27/2014","primary_txt":" Primary completion: 07/31/2019","primary_completion_date":" 07/31/2019","study_txt":" Completion: 07/31/2019","study_completion_date":" 07/31/2019","last_update_posted":"2021-01-28"},{"id":"60f58674-5486-4586-a18d-855353716efc","acronym":"","url":"https://clinicaltrials.gov/study/NCT04215367","created_at":"2021-01-19T08:29:55.444Z","updated_at":"2024-07-02T16:36:51.972Z","phase":"","brief_title":"Dietary Intervention With High Phenolic EVOO in CLL","source_id_and_acronym":"NCT04215367","lead_sponsor":"University of Peloponnese","biomarkers":" FAS","pipe":"","alterations":" ","tags":["FAS"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 12/15/2018","start_date":" 12/15/2018","primary_txt":" Primary completion: 06/05/2019","primary_completion_date":" 06/05/2019","study_txt":" Completion: 12/05/2019","study_completion_date":" 12/05/2019","last_update_posted":"2020-01-02"},{"id":"46c08f17-26c5-4730-b84c-c4364ca8da5f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02545361","created_at":"2021-01-19T08:29:28.970Z","updated_at":"2024-07-02T16:37:07.837Z","phase":"Phase 1/2","brief_title":"Safety, Tolerability, and Anti-cancer Activity of KAHR-102 (The Study Drug) for the Treatment of Lymphoma Patients","source_id_and_acronym":"NCT02545361","lead_sponsor":"Kahr Medical","biomarkers":" FAS • CD80 • CD86","pipe":"","alterations":" ","tags":["FAS • CD80 • CD86"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KAHR-102 • dexamethasone injection"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 04/01/2018","start_date":" 04/01/2018","primary_txt":" Primary completion: 04/01/2020","primary_completion_date":" 04/01/2020","study_txt":" Completion: 04/01/2020","study_completion_date":" 04/01/2020","last_update_posted":"2018-08-16"},{"id":"5020829b-800d-4f72-8e51-21d79cf2be23","acronym":"","url":"https://clinicaltrials.gov/study/NCT01324258","created_at":"2021-01-18T05:23:32.137Z","updated_at":"2024-07-02T16:37:16.419Z","phase":"Phase 1","brief_title":"Trial of GSK1120212 and GSK1120212 in Combination With GEM in Japanese Subjects With Solid Tumors","source_id_and_acronym":"NCT01324258","lead_sponsor":"GlaxoSmithKline","biomarkers":" KRAS • BRAF • FAS","pipe":" | ","alterations":" KRAS mutation • BRAF mutation","tags":["KRAS • BRAF • FAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • gemcitabine"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 01/24/2011","start_date":" 01/24/2011","primary_txt":" Primary completion: 07/08/2013","primary_completion_date":" 07/08/2013","study_txt":" Completion: 07/08/2013","study_completion_date":" 07/08/2013","last_update_posted":"2017-11-13"},{"id":"534116f7-4edf-411d-8100-f2f1c32df7f4","acronym":"","url":"https://clinicaltrials.gov/study/NCT03152708","created_at":"2021-01-18T15:32:18.729Z","updated_at":"2024-07-02T16:37:17.654Z","phase":"","brief_title":"CAN008 Biomarker CD95 Ligand and CpG2 Methylation in Chinese Patients With Glioblastoma","source_id_and_acronym":"NCT03152708","lead_sponsor":"CANbridge Life Sciences Ltd.","biomarkers":" FAS","pipe":"","alterations":" ","tags":["FAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Apocept (asunercept)"],"overall_status":"Unknown status","enrollment":" Enrollment 62","initiation":"Initiation: 11/01/2017","start_date":" 11/01/2017","primary_txt":" Primary completion: 12/01/2017","primary_completion_date":" 12/01/2017","study_txt":" Completion: 12/31/2017","study_completion_date":" 12/31/2017","last_update_posted":"2017-09-21"}]